Quanterix Corp - Understand $qtrx stock

$QTRX Market Cap: $542.7 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$129.3M

TTM

Gross Margin

57.39%

TTM

Net Earnings

-$39.71M

TTM

Current Assets

$365.7M

Q2 2024

Current Liabilities

$37.54M

Q2 2024

Current Ratio

974.26%

Q2 2024

Total Assets

$411.3M

Q2 2024

Total Liabilities

$74.54M

Q2 2024

Book Value

$336.8M

Q2 2024

Cash

$47.00M

Q2 2024

P/E

-13.67

Sep 18, 2024 EST

Free Cash Flow

-$40.26M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$122.4M	$105.5M	$110.6M	$86.38M	$56.73M	$37.63M	$22.87M	$17.59M	$12.18M
YoY Change	15.96%	-4.55%	27.99%	52.25%	50.76%	64.55%	30.02%	44.42%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$122.4M	$105.5M	$110.6M	$86.38M	$56.73M	$37.63M	$22.87M	$17.59M	$12.18M
Cost Of Revenue	$51.72M	$58.72M	$48.83M	$38.20M	$29.90M	$19.68M	$12.89M	$9.840M	$6.470M
Gross Profit	$70.65M	$46.81M	$61.73M	$48.18M	$26.84M	$17.95M	$9.990M	$7.750M	$5.720M
Gross Profit Margin	57.73%	44.36%	55.83%	55.78%	47.3%	47.69%	43.68%	44.06%	46.96%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	$90.24M	$92.00M	$92.34M	$59.59M	$52.25M	$33.69M	$19.69M	$12.47M	$10.16M
YoY Change	-1.91%	-0.37%	54.95%	14.06%	55.06%	71.12%	57.9%	22.74%
% of Gross Profit	127.74%	196.55%	149.59%	123.68%	194.69%	187.73%	197.1%	160.9%	177.62%
Research & Development	$24.86M	$25.89M	$27.98M	$20.17M	$16.19M	$15.81M	$16.30M	$16.99M	$10.08M
YoY Change	-3.99%	-7.46%	38.68%	24.61%	2.44%	-3.04%	-4.06%	68.55%
% of Gross Profit	35.19%	55.31%	45.32%	41.87%	60.33%	88.06%	163.16%	219.23%	176.22%
Depreciation & Amortization	$4.700M	$3.500M	$2.800M	$2.200M	$1.600M	$1.350M	$480.0K	$440.0K	$430.0K
YoY Change	34.29%	25.0%	27.27%	37.5%	18.52%	181.25%	9.09%	2.33%
% of Gross Profit	6.65%	7.48%	4.54%	4.57%	5.96%	7.52%	4.8%	5.68%	7.52%
Operating Expenses	$120.3M	$148.5M	$120.3M	$79.77M	$68.44M	$49.50M	$35.99M	$29.46M	$20.23M
YoY Change	-18.96%	23.44%	50.83%	16.56%	38.26%	37.53%	22.17%	45.63%
Operating Profit	-$49.70M	-$101.7M	-$58.59M	-$31.58M	-$41.60M	-$31.55M	-$26.00M	-$21.71M	-$14.51M
YoY Change	-51.13%	73.6%	85.49%	-24.08%	31.85%	21.35%	19.76%	49.62%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Interest Expense	$15.84M	$5.131M	-$403.0K	-$270.0K	$630.0K	$50.00K	-$950.0K	-$1.300M	-$1.040M
YoY Change	208.69%	-1373.2%	49.26%	-142.86%	1160.0%	-105.26%	-26.92%	25.0%
% of Operating Profit
Other Income/Expense, Net	$2.247M	-$62.00K	$1.265M	-$49.00K	-$10.00K	-$7.000K	-$60.00K	-$160.0K	-$380.0K
YoY Change	-3724.19%	-104.9%	-2681.63%	390.0%	42.86%	-88.33%	-62.5%	-57.89%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Pretax Income	-$31.62M	-$96.64M	-$57.72M	-$31.91M	-$40.98M	-$31.51M	-$27.02M	-$23.17M	-$15.94M
YoY Change	-67.28%	67.41%	80.92%	-22.15%	30.06%	16.62%	16.62%	45.36%
Income Tax	$719.0K	$65.00K	-$36.00K	-$376.0K	-$187.0K	$0.00		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$32.33M	-$96.70M	-$57.70M	-$31.53M	-$40.80M	-$31.50M	-$27.02M	-$23.17M	-$15.94M
YoY Change	-66.56%	67.59%	83.0%	-22.71%	29.51%	16.58%	16.62%	45.36%
Net Earnings / Revenue	-26.42%	-91.64%	-52.19%	-36.5%	-71.91%	-83.71%	-118.15%	-131.72%	-130.87%
Basic Earnings Per Share	-$0.86	-$2.61	-$1.60	-$1.07	-$1.63
Diluted Earnings Per Share	-$0.86	-$2.61	-$1.60	-$1.07	-$1.63	-$1.434M	-$7.186M	-$1.145M	-$787.5K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Short-Term Investments	$321.3M	$338.7M	$396.5M	$181.6M	$109.2M	$44.40M	$79.70M	$29.70M	$2.300M
YoY Change	-5.14%	-14.56%	118.32%	66.3%	145.95%	-44.29%	168.35%	1191.3%
Cash & Equivalents	$174.4M	$338.7M	$396.5M	$181.6M
Short-Term Investments	$146.9M				$102.7M	$42.60M	$78.20M	$0.00	$300.0K
Other Short-Term Assets	$9.291M	$6.860M	$6.514M	$6.000M	$2.100M	$2.300M	$400.0K	$100.0K	$100.0K
YoY Change	35.44%	5.31%	8.57%	185.71%	-8.7%	475.0%	300.0%	0.0%
Inventory	$22.37M	$16.79M	$22.19M	$14.90M	$10.50M	$5.900M	$3.600M	$1.500M	$1.000M
Prepaid Expenses
Receivables	$25.41M	$19.02M	$23.79M	$17.20M	$10.90M	$6.800M	$5.600M	$3.900M	$2.300M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$378.4M	$381.4M	$449.0M	$219.6M	$132.7M	$59.50M	$89.30M	$35.20M	$5.700M
YoY Change	-0.79%	-15.05%	104.44%	65.49%	123.03%	-33.37%	153.69%	517.54%
Property, Plant & Equipment	$36.18M	$41.39M	$29.45M	$25.90M	$12.00M	$2.900M	$1.900M	$1.200M	$1.100M
YoY Change	-12.58%	40.52%	13.71%	115.83%	313.79%	52.63%	58.33%	9.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.406M	$3.895M	$2.955M	$1.400M	$1.600M	$1.500M	$700.0K	$700.0K	$600.0K
YoY Change	13.12%	31.81%	111.07%	-12.5%	6.67%	114.29%	0.0%	16.67%
Total Long-Term Assets	$46.62M	$52.80M	$52.57M	$51.40M	$37.30M	$8.100M	$2.500M	$1.900M	$1.700M
YoY Change	-11.7%	0.43%	2.28%	37.8%	360.49%	224.0%	31.58%	11.76%
Total Assets	$425.0M	$434.2M	$501.5M	$271.0M	$170.0M	$67.60M	$91.80M	$37.10M	$7.400M
YoY Change
Accounts Payable	$5.048M	$3.836M	$9.209M	$6.800M	$5.800M	$5.100M	$3.600M	$2.500M	$1.300M
YoY Change	31.6%	-58.35%	35.43%	17.24%	13.73%	41.67%	44.0%	92.31%
Accrued Expenses	$23.94M	$18.09M	$21.17M	$16.90M	$9.100M	$7.600M	$6.200M	$4.100M	$2.900M
YoY Change	32.33%	-14.52%	25.24%	85.71%	19.74%	22.58%	51.22%	41.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00	$7.700M	$100.0K	$0.00	$5.000M	$900.0K	$2.100M
YoY Change			-100.0%	7600.0%		-100.0%	455.56%	-57.14%
Total Short-Term Liabilities	$38.46M	$30.96M	$36.98M	$39.80M	$19.80M	$18.10M	$19.70M	$11.00M	$7.800M
YoY Change	24.22%	-16.28%	-7.09%	101.01%	9.39%	-8.12%	79.09%	41.03%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$7.600M	$7.600M	$4.300M	$12.10M	$13.20M
YoY Change				-100.0%	0.0%	76.74%	-64.46%	-8.33%
Other Long-Term Liabilities	$38.45M	$42.83M	$21.56M	$22.50M	$13.90M	$800.0K	$1.900M	$500.0K	$1.600M
YoY Change	-10.23%	98.64%	-4.16%	61.87%	1637.5%	-57.89%	280.0%	-68.75%
Total Long-Term Liabilities	$38.45M	$42.83M	$21.56M	$22.50M	$21.50M	$8.400M	$6.200M	$12.60M	$14.80M
YoY Change	-10.23%	98.64%	-4.16%	4.65%	155.95%	35.48%	-50.79%	-14.86%
Total Liabilities	$78.08M	$75.26M	$60.58M	$64.90M	$41.30M	$26.50M	$25.90M	$23.60M	$22.50M
YoY Change	3.75%	24.24%	-6.66%	57.14%	55.85%	2.32%	9.75%	4.89%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	37.59M	36.99M	36.00M	29.59M	25.09M
Diluted Shares Outstanding	37.59M	36.99M	36.00M	29.59M	25.09M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $542.68 Million

About Quanterix Corp

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The firm's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. The company also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. The company has completed over 2,200 projects for 480 customers using its Simoa platforms.

Industry: Laboratory Analytical Instruments Peers: Absci Corp Akoya Biosciences Inc Nautilus Biotechnology Inc Bruker Cellular Analysis, Inc. Inotiv, Inc. Codexis Inc Quantum-Si Inc Science 37 Holdings, Inc. Seer Inc Thermo Fisher Scientific Inc